The use of photodynamic therapy in the management of darier disease and Hailey-Hailey disease: a systematic review.


Journal

Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 12 08 2024
accepted: 26 08 2024
revised: 13 08 2024
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: epublish

Résumé

Darier disease and Hailey-Hailey disease are rare autosomal dominant genodermatoses that negatively impact patient quality of life. In addition, they pose challenges to dermatologists who manage these diseases. There is currently no treatment that reliably induces remission for either disease, leaving patients dependent on symptom management. Oral and topical retinoids are the most commonly used therapies but have numerous side effects that often lead to discontinuation or inability to tolerate long-term treatment (Burge and Wilkinson in J Am Acad Dermatol 27:40-50, 1992). Due to the rarity of these diseases, there are no clinical trials investigating treatment options for the persistent flares patients experience. In light of this, dermatologists have tried various methods used in the management of other inflammatory disorders including photodynamic therapy (PDT). A systematic review was conducted to investigate this treatment option which yielded a total of 12 studies that had reported the use of photodynamic therapy (PDT) as a treatment option for Darier or Hailey-Hailey disease. Though results showed that PDT can induce disease remission for up to several months or years, there are many unanswered questions that need to be addressed before adopting PDT as a leading treatment option for those genodermatoses. In particular, cost, tolerability, and efficacy and safety in patients who are skin of color need to be further studied. Lastly, recommendations on treatment duration, number of sessions, photosensitizing agents, lasers, and continuation or discontinuation of topical and systemic medications need to be appraised before formal recommendations can be made.

Identifiants

pubmed: 39259372
doi: 10.1007/s00403-024-03356-8
pii: 10.1007/s00403-024-03356-8
doi:

Substances chimiques

Photosensitizing Agents 0

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

610

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Burge SM, Wilkinson JD (1992) Darier-white disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 27(1):40–50. https://doi.org/10.1016/0190-9622(92)70154-8
doi: 10.1016/0190-9622(92)70154-8 pubmed: 1619075
Christman MP, Reider E, Kim RH, Brinster N, Femia E, Pomeranz MK (2016) Darier-white disease. Dermatol Online J 22(12):13030
doi: 10.5070/D32212033388
Teplyuk N, Lepekhova A, Dunaeva E, Smirnov K, Perunova A (2023) Hailey-Hailey disease successfully treated with photodynamic therapy: case report. Photodiagnosis Photodyn Ther 44:103738. https://doi.org/10.1016/j.pdpdt.2023.103738 . (Epub 2023 Aug 8 PMID: 37558191)
doi: 10.1016/j.pdpdt.2023.103738 pubmed: 37558191
Lobefaro F, Gualdi G, Andreassi G, Amerio P (2022) Sequential treatments of Hailey-Hailey disease with photodynamic therapy, botulinum toxin type A and dapsone: a case report. Dermatol Ther 35(12):e15841. https://doi.org/10.1111/dth.15841
doi: 10.1111/dth.15841 pubmed: 36124888
Martora F, Ruggiero A, Fornaro L, Fabbrocini G, Marasca C (2022) Photodynamic therapy with 16 methyl aminolaevulinic acid and topic calcipotriol: a novel promising synergistic approach for the management of Hailey-Hailey disease. Photodiagnosis Photodyn Ther 39:103018. https://doi.org/10.1016/j.pdpdt.2022.103018 . (Epub 2022 Jul 16 PMID: 35850460)
doi: 10.1016/j.pdpdt.2022.103018 pubmed: 35850460
Alsahli M, Debu A, Girard C, Bessis D, Du Thanh A, Guillot B, Dereure O (2017) Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey–Hailey disease)? A series of eight patients. J Dermatol Treatment 28(7):678–682. https://doi.org/10.1080/09546634.2017.1308461
doi: 10.1080/09546634.2017.1308461
Lobato-Berezo A, Imbernón-Moya A, Aguilar-Martínez A (2015) Refractory Hailey-Hailey disease that responded well to photodynamic therapy. Actas Dermo-Sifiliogr 106(10):852–854. https://doi.org/10.1016/j.adengl.2015.10.008
doi: 10.1016/j.adengl.2015.10.008
Scarabello A, Pulvirenti C, Adebanjo G, Parisella F, Chello C, Tammaro A (2022) Photodynamic therapy with 5 aminolaevulinic acid: a promising therapeutic option for the treatment of Hailey-Hailey disease. Photodiagnosis Photodyn Therapy 38:102794. https://doi.org/10.1016/j.pdpdt.2022.102794
doi: 10.1016/j.pdpdt.2022.102794
Yan XX, Tian HQ, Wang CL, Yang BQ, Wu WZ, Zhang FR (2015) Successful treatment of hailey-hailey disease with aminolevulinic acid photodynamic therapy. Ann Dermatol 27(2):222–223. https://doi.org/10.5021/ad.2015.27.2.222
doi: 10.5021/ad.2015.27.2.222 pubmed: 25834370 pmcid: 4377420
Fernández Guarino M, Ryan AM, Harto A, Pérez-García B, Arrázola JM, Jaén P (2008) Experience with photodynamic therapy in Hailey-Hailey disease. J Dermatolog Treat 19(5):288–290. https://doi.org/10.1080/09546630801958220 . (PMID: 18608733)
doi: 10.1080/09546630801958220 pubmed: 18608733
Ruiz-Rodriguez R, Alvarez JG, Jaén P, Acevedo A, Córdoba S (2002) Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 47:740–742
doi: 10.1067/mjd.2002.124802 pubmed: 12399767
Morelló-Vicente A, Antoñanzas J, Estenaga Á, Oteiza-Rius I, Salido-Vallejo R, España A (2022) Refractory facial Darier’s disease treated with daylight photodynamic therapy. JDDG: J der Deutsche Dermatol Gesell 20:1633–1635. https://doi.org/10.1111/ddg.14909
doi: 10.1111/ddg.14909
Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ (2003) Treatment of Darier’s disease with photodynamic therapy. Br J Dermatol 149(3):606–610. https://doi.org/10.1046/j.1365-2133.2003.05494.x
doi: 10.1046/j.1365-2133.2003.05494.x pubmed: 14510996

Auteurs

Olivia Ueltschi (O)

The Ohio State University College of Medicine, Columbus, OH, 43210, USA. olivia.ueltschi@osumc.edu.

Marisa Casola (M)

The Ohio State University College of Medicine, Columbus, OH, 43210, USA.

Lucy Rose (L)

The Ohio State University College of Medicine, Columbus, OH, 43210, USA.

Brittany Dulmage (B)

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.

Jessica Kaffenberger (J)

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH